Hope for millions? Scientists discover brain's 'cleanup system' could fight Alzheimer's with existing drugs

A ray of hope has emerged for the millions living with Alzheimer's, as scientists uncover a groundbreaking new avenue for dementia treatment. Researchers have revealed how a natural brain neurotransmitter could turn harmful brain cells into a 'protective mode', potentially using existing, FDA-approved drugs.

The Brain's Own Defence

Alzheimer's disease typically worsens when a protein called amyloid beta builds up in the brain. This triggers the brain's immune cells, known as microglia, to become overactivated and cause inflammation.

Initially, microglia help by clearing amyloid plaques. However, over time, they turn rogue, damaging vital brain synapses and fuelling inflammation.

Switching to 'Protective Mode'

The breakthrough, led by Professor Jiwon Um at DGIST, found that a brain neurotransmitter called somatostatin can prevent this harmful overactivation. It directly regulates microglia, restoring their crucial role as the brain's own cleanup system.

When somatostatin was applied to these cells in the lab, their waste-engulfing function dramatically improved. The team also observed a significant drop in inflammatory substances.

Brain-damaging inflammatory factors were suppressed, while anti-inflammatory factors increased. This effectively switched the immune cells into a gentle 'protective state'.

Boosting Brain Power

The research team further tested this by increasing somatostatin levels in mice with Alzheimer’s. They successfully suppressed the immune cell overactivation that causes inflammation.

This also substantially reduced the accumulation of amyloid waste across the brain. Crucially, the mice showed a statistically significant improvement in long-term spatial memory, indicating a meaningful cognitive boost.

Professor Um emphasised: “This study demonstrates for the first time that somatostatin, a brain neurotransmitter, can directly regulate the state of immune cells to alleviate dementia pathology and improve memory function.”

Existing Drugs, New Hope

These findings are particularly exciting as they could massively speed up the development of new treatments. The study points towards 'drug repurposing' – using medications already approved for other conditions.

The somatostatin receptor (SSTR) targeted in this research is already widely used clinically. It has FDA approval for treating conditions like acromegaly.

Previous Alzheimer's trials for somatostatin-related drugs faced hurdles in delivering them to the brain. However, this study pinpointed the exact mechanism by which the treatment targets microglia.

Professor Um added: “Previous clinical trials for dementia faced significant limitations. However, drugs already approved and used to treat other conditions now show new potential for application in treating dementia and neuroinflammation based on this newly discovered mechanism.”

The paper was published online on March 26, 2026, in the journal Brain, Behavior, and Immunity. It was jointly first-authored by Dr. Hyeji Jung and master’s student Gaeun Hyun from DGIST.

Related Content

MORE: New breakthrough grows "gentle" immune cells to kill cancer without nasty side effects — https://trendwiremedia.com/2026/03/12/new-breakthrough-grows-gentle-immune-cells-to-kill-cancer-without-nasty-side-effects/

MORE: Bloodhound' immune cells follow their noses to hunt and kill tumours — https://trendwiremedia.com/2026/03/27/bloodhound-immune-cells-follow-their-noses-to-hunt-and-kill-tumours/

MORE: Scientists map 30 million cells to find the 'hidden origins' of autism and dementia — https://trendwiremedia.com/2026/03/29/scientists-map-30-million-cells-to-find-the-hidden-origins-of-autism-and-dementia/

OFFICIAL SOURCE VERIFICATION: This report is based on official data from University Newsroom. Document: Confirming the Potential to Treat Dementia with FDA-Approved Drugs DGIST Discovers Treatment Mechanism to Calm Brain Immune Cells Source Link: [Read the official report from University Newsroom](https://www.asiaresearchnews.com/node/22610)